Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
6
×
clinical trials
fda
life sciences
national blog main
new york top stories
europe top stories
national top stories
new york blog main
san diego blog main
san diego top stories
san francisco top stories
boston blog main
boston top stories
europe blog main
indiana blog main
indiana top stories
national
san francisco blog main
akcea therapeutics
alnylam pharmaceuticals
arena pharmaceuticals
barry greene
bial
billy dunn
biogen
boehringer ingelheim
boston
boston university
boulder/denver blog main
boulder/denver top stories
cancer
cardiovascular disease
colorectal cancer
dan ollendorf
detroit blog main
detroit top stories
digital therapeutics
drug development
drug prices
What
fda
6
×
patients
6
×
drug
medicine
daily
friday
gets
home
new
therapy
time
add
ago
alnylam
app
approval
approve
approved
atrophy
awaits
based
bid
biofourmis
biological
boehringer
boston
breakthrough
called
cancer
carbidopa
closer
combination
company
control
crossed
decades
decision
designation
device
diabetes
Language
unset
Current search:
patients
×
biotech
×
fda
×
@techcrunch.com
2 years ago
Biofourmis receives FDA breakthrough device designation for heart failure “digital therapy”
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision